The Business Behind...
Health Care: Drugs
Synta Pharmaceuticals Inc. (SNTA: NASDAQ)
$7.51 0.08 | 1.08%
05/21/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 7.43 |
| 52 Week High | 11.88 |
| 52 Week Low | 4.10 |
| Avg. Daily Vol. (Mil) | 0.71 |
| Beta (3 year) | 2.39 |
| Share Related Items | |
| Mkt Cap (Mil) | 513.66 |
| Shares Out (Mil) | 69.13 |
| Float (Mil) | 32.23 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 5.50 |
| Current Ratio | 5.60 |
| LT Debt/ Equity | 0.36 |
| Total Debt / Equity | 0.42 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 0.00 |
| Price/Book | 9.07 |
| Price/Cash Flow | -6.20 |
| Per Share Data | |
| Earnings | -1.09 |
| Sales | 0.00 |
| Book Value | 0.82 |
| Cash Flow | -1.20 |
| Business Summary | |
|---|---|
| A biopharmaceutical company, which is focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. | |
| General Information | |
| 45 Hartwell Avenue
Lexington, MA 02421 |
|
| www.syntapharma.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 124 | |
| CEO: Dr. Safi R. Bahcall,PhD | |
| Short Interest | |
| Current Month (Mil) | 8.70 |
| Previous Month (Mil) | 8.32 |
| Short Interest Ratio (Days) | 16.80 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -89.10 |
| Return on Investments | -108.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with SNTA
- Portfolio NameUser Type
- ContributorEarnings Short Squeeze Play...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks With Big Insider Buy...
- UserPharma
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
- Userinsider buying
Latest SNTA Headlines from TheStreet
- Synta Is a Run-Up Trade Into ASCO Lung Cancer Data 05.14.13 | 10:05 am
- Biotech Stock Mailbag: Synta, Zogenix, Sarepta, Amarin 05.10.13 | 07:05 am
- Synta Pharmaceuticals Becomes Oversold (SNTA) 05.08.13 | 04:05 pm
- Biotech Stock Mailbag: ASCO, Sarepta, Cel-Sci and Hate Mail! 04.26.13 | 08:04 am
- Insiders Trading GHDX ASCMA GNC SNTA 11.15.12 | 09:11 am
- The Next Big Thing in Biotech: Cancer Drugs
09.21.12 | 07:09 am - 5 Stocks Under $10 Set to Soar 09.20.12 | 01:09 pm
- 5 Stocks Under $10 Soaring Higher 09.13.12 | 02:09 pm
- 5 Stocks With Huge Insider Buying 07.11.12 | 10:07 am
- Insiders Trading SNTA, VMW, ENSG, AFG 07.03.12 | 10:07 am
Press Releases for SNTA
- Synta Provides Company Updates And Reports Fourth Quarter And Year-End 2012 Financial Results - Business Wire 03.14.13 | 07:03 am
- Synta Announces Appointment Of Sumant Ramachandra, M.D., Ph.D. As President, Research And Development - Business Wire 03.13.13 | 04:03 pm
- Synta To Host Conference Call And Webcast Of Fourth Quarter And Year-End 2012 Financial Results On March 14, 2013 - Business Wire 02.25.13 | 07:02 am
- Synta To Present At Upcoming Conferences - Business Wire 02.11.13 | 08:02 am
- Synta Pharmaceuticals Announces $60 Million Registered Direct Common Stock Offering - Business Wire 12.13.12 | 07:12 am
- Synta Pharmaceuticals Announces Proposed Registered Direct Offering Of Common Stock - Business Wire 12.12.12 | 04:12 pm
- Synta To Present At The Deutsche Bank 2012 DbAccess BioFEST - Business Wire 11.27.12 | 07:11 am
- Interim Results Of The Phase 2b/3 GALAXY Trial To Be Presented At The Fifth Asia Pacific Lung Cancer Conference - Business Wire 11.26.12 | 07:11 am
- Synta To Present At The Lazard Capital Markets 9th Annual Healthcare Conference - Business Wire 11.09.12 | 08:11 am
- Interim Results Of The Phase 2b GALAXY Trial To Be Presented At The Chemotherapy Foundation Symposium - Business Wire 11.07.12 | 08:11 am
Partner Headlines for SNTA
- BlackBerry Will Underperform and 4 More Analyst Notes to Looks At - Wall St. Cheat Sheet 04.01.13 | 04:04 am
- BlackBerry Will Underperform and 4 More Analyst Notes to Looks At - Wall St. Cheat Sheet 04.01.13 | 04:04 am
- Trius Therapeutics: New MSRA Treatment Could Bring Billions In Revenues - Seeking Alpha 03.05.13 | 09:03 am
- Insiders Love These 3 Highly Shorted Healthcare Stocks - Seeking Alpha 01.23.13 | 09:01 am
- UPDATE: Stifel Nicolaus Initiates Synta Pharmaceuticals at Hold; Enthusiasm Outpaces Expectations - Benzinga 08.30.12 | 01:08 pm
- Weekly CEO Buys Highlight: SNTA, MEI, PZG, MCHX, CMXI - GuruFocus 07.07.12 | 11:07 pm
- Vertex Pharmaceuticals CRASHES 16% with 3 NASDAQ Top Percentage Losers - Wall St. Cheat Sheet 06.29.12 | 10:06 am
- Healthcare Business Recap: Orexigen RIDES Arena, Anthera IMPLODES - Wall St. Cheat Sheet 06.28.12 | 08:06 am
- Analyst Says BUY Arena and 4 Equity Insights to Analyze Now - Wall St. Cheat Sheet 06.28.12 | 03:06 am
- New Lease Agreements for Alexandria - Analyst Blog - Zacks 06.08.12 | 05:06 pm
